Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Outcomes of hospitalized patients with hyperferritinemia and hematologic malignancies: A single-center retrospective analysis

Rishi Bothara, Duaa Kanan, Simon Bechara et al. Nov 03, 2025 pp. 8179-8179 10.1182/blood-2025-8179

Abstract Background Hyperferritinemia is associated with systemic inflammation and adverse clinical outcomes. Its prognostic significance in...

Real-world outcomes associated with azacitidine and venetoclax in Myelodysplastic Syndromes

Taylor Kujawa, Stacy Prelewicz, Clara Davis et al. Nov 03, 2025 pp. 8193-8193 10.1182/blood-2025-8193

Abstract Introduction: Myelodysplastic syndromes (MDS) are hematologic malignancies characterized by bone marrow failure and risk for progre...

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Sara Scott, Ajay Nooka, Jonathan Kaufman et al. Nov 03, 2025 pp. 2811-2811 10.1182/blood-2025-2811

Abstract Introduction: Bridging treatment prior to administration of chimeric antigen receptor (CAR) T-cells in patients with relapsed/refra...

Evaluating the implementation of an electronic patient-reported outcome system supporting self-management of treatment-related impairments among patients with lymphoma

Christian Lopez, Jennifer Jones, Anthony Reiman et al. Nov 03, 2025 pp. 2639-2639 10.1182/blood-2025-2639

Abstract Introduction: Patients treated for lymphoma often experience a high burden of treatment-related impairments that, when left unaddre...

iPSC-derived mesenchymal stromal cells (iMSC) provide superior support for hematopoietic reconstitution compared to BM-MSCs

Olayinka Okeleji, Sandeep Singh, Andrea Bedoy et al. Nov 03, 2025 pp. 4957-4957 10.1182/blood-2025-4957

Abstract Background Mesenchymal stromal cells (MSCs) have demonstrated therapeutic promise in regenerative medicine and hematopoietic suppor...

Generation of iNKT cells with hematopoiesis-promoting properties from human iPSCs

Saritha D'Souza, Akhilesh Kumar, Sara Ferguson et al. Nov 03, 2025 pp. 4184-4184 10.1182/blood-2025-4184

Abstract Human invariant natural killer T (iNKT) cells are a conserved population of innate-like T cells that are activated by glycolipid an...

Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

Warren Fiskus, Christopher Mill, Lucia Masarova et al. Nov 03, 2025 pp. 5053-5053 10.1182/blood-2025-5053

Abstract In MPN stem/progenitor cells, the co-occurrence of additional mutations in chromatin/transcriptional regulators such as DNMT3A, ASX...

Pharmacodynamic analysis of AGAVE-201 indicates changes in CSF-1R–expressing cells and associated biomarkers potentially contributing to chronic graft-versus-host disease resolution

Michael Pratta, Angelina Volkova, Ian Catlett et al. Nov 03, 2025 pp. 2458-2458 10.1182/blood-2025-2458

Abstract Introduction: Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and nonrelapse mortality among patients who u...

Hematologic malignancies in pediatric patients with RUNX1-familial platelet disorder with associated myeloid malignancy

Amra Kajdic, Natalie Deuitch, Erica Bresciani et al. Nov 03, 2025 pp. 1437-1437 10.1182/blood-2025-1437

Abstract RUNX1 is a transcription factor crucial for normal hematopoiesis. Deleterious germline RUNX1 variants cause Familial Platelet Disor...

Baseline T-cell fitness and subtype-specific CD19 loss as drivers of blinatumomab resistance in B-ALL

Sonja Bendig, Miriam Kelm, Anna Laqua et al. Nov 03, 2025 pp. 32-32 10.1182/blood-2025-32

Abstract The introduction of Blinatumomab (BLIN), a bispecific T-cell engager targeting CD19, has marked a major advancement in B-ALL therap...

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Chrissy Baker, Elizabeth Hill, Dickran Kazandjian et al. Nov 03, 2025 pp. 3920-3920 10.1182/blood-2025-3920

Abstract Introduction In multiple myeloma (MM), assessment of minimal residual disease (MRD) is limited by a need for serial bone marrow (mar...

Travel time and insurance status as determinants of specialized leukemia care access in adolescents and young adult (AYA) patients with acute lymphoblastic leukemia (ALL)

Lori Muffly, Helen Parsons, Katharine Miller et al. Nov 03, 2025 pp. 283-283 10.1182/blood-2025-283

Abstract Background: NCCN guidelines for ALL state that patients should undergo evaluation and treatment at specialized [cancer] centers (SC...

Pyruvate kinase deficiency is associated with mitochondrial retention, decreased antioxidant and HIFs activity correlating with hemolysis

Jihyun Song, Soo Jin Kim, Changwhan Moon et al. Nov 03, 2025 pp. 2896-2896 10.1182/blood-2025-2896

Abstract Pyruvate kinase deficiency (PKD), caused by loss-of-function mutations in the PKLR gene, is a rare autosomal recessive disorder but...

Pilot of standardized cognitive behavioral therapy for young adults with sickle cell disease

Roy Kao, Timothy Moore, Jacob Cogan et al. Nov 03, 2025 pp. 4752-4752 10.1182/blood-2025-4752

Abstract The success in minimizing sickle cell disease (SCD) morbidity in pediatrics has often been difficult to maintain upon moving to adu...

Single-cell transcriptomic analysis reveals ifng/IL-6-mediated inflammatory networks in der(1;7)(q10;p10) Myelodysplastic Syndromes

Wei Wang, Yingwan Luo, Wei Lang et al. Nov 03, 2025 pp. 5617-5617 10.1182/blood-2025-5617

Abstract Background: Der(1;7)(q10;p10)[der(1;7)] as a recurrent unbalanced translocation in MDS has steadily gained attention. The direct co...

Response-adapted randomization to Q2W vs Q4W isatuximab beyond cycle 6 in relapsed multiple myeloma: Results from a phase 2 Study of isa-pd in lenalidomide- and PI-exposed patients

Evangelos Terpos, Maria Gavriatopoulou, Vasiliki Lampropoulou et al. Nov 03, 2025 pp. 4037-4037 10.1182/blood-2025-4037

Abstract Introduction: Isatuximab (Isa), an anti-CD38 mAb, is approved with pomalidomide and low-dose dexamethasone (Isa-Pd) for RRMM after ≥...

Gene expression profiling of pediatric mature B-cell non-Hodgkin lymphomas/lymphoproliferative disorders through whole transcriptome analysis

Yen-Chun Liu, Yiping Fan, Matthew Ehrhardt et al. Nov 03, 2025 pp. 7052-7052 10.1182/blood-2025-7052

Abstract Background: Adult and pediatric mature B-cell non-Hodgkin lymphomas/lymphoproliferative disorders (ped mature B-NHL/LPDs) differ bo...

The unseen bleed- temporal and demographic patterns of thrombocytopenia mortality in the United States: A 25-year analysis of the CDC wonder database

Sandhya Rani Reddy, Nayanika Tummala, Hakim Wazir et al. Nov 03, 2025 pp. 6595-6595 10.1182/blood-2025-6595

Abstract The Unseen Bleed- Temporal and Demographic Patterns of Thrombocytopenia Mortality in the United States: A 25-Year Analysis of the C...

Feasibility and preliminary efficacy of a Mediterranean diet and home-based exercise intervention during chemotherapy for lymphoma survivors: The life-l study

Melissa Lopez-Pentecost, Tracy Crane, Akina Natori et al. Nov 03, 2025 pp. 4547-4547 10.1182/blood-2025-4547

Abstract Introduction: Lymphoma patients undergoing chemotherapy often face toxicities that affect treatment completion and quality of life....

Incidence, predictors and consequences of poor graft function after post-transplant cyclophosphamide (PTCy)-based allogeneic transplantation

Lizamarie Bachier Rodriguez, Asad Bashey, H. Kent Holland et al. Nov 03, 2025 pp. 7709-7709 10.1182/blood-2025-7709

Abstract Prolonged cytopenias requiring transfusion and growth factor support are a known complication of allogeneic hematopoietic stem cell...

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Robert Orlowski, Mansi Shah, Rajshekhar Chakraborty et al. Nov 03, 2025 pp. 697-697 10.1182/blood-2025-697

Abstract Introduction Treatment of NDMM relies on complex quads and triplets, highlighting a need for a simpler, improved regimen. LINVO, a...

Ribosome biogenesis and its regulation by the exportin, CSE1L, are targetable vulnerabilities in childhood and young adult Acute Myeloid Leukemia

Grace Egan, Amit Kumar, Veronique Voisin et al. Nov 03, 2025 pp. 1452-1452 10.1182/blood-2025-1452

Abstract There are fundamental differences in the genomic drivers of childhood, adolescent and young adult (AYA) acute myeloid leukemia (AML...

Extreme thrombocytosis in patients with underlying malignancy; Management, complications and outcomes.

Laura McDonald, Heba Hasan, Lorelyn Donato et al. Nov 03, 2025 pp. 6591-6591 10.1182/blood-2025-6591

Abstract Thrombocytosis is a commonly seen haematological abnormality. However, extreme thrombocytosis (EXT, defined as a platelet count of...

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Richard Lin, Soo Jung Kim, Maria Bromberg et al. Nov 03, 2025 pp. 6296-6296 10.1182/blood-2025-6296

Abstract Introduction: CAR T therapy has revolutionized treatment landscape for patients with relapsed refractory (R/R) non-Hodgkin's lympho...

Impact of a near-peer group mentorship program on improving transition skills for adolescents and young adults living with sickle cell disease

Midori Hosoda, Kepler Jeudy, Kimberly Vasquez et al. Nov 03, 2025 pp. 4437-4437 10.1182/blood-2025-4437

Abstract Introduction People living with sickle cell disease (SCD) often have short life expectancies and are deeply aff...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page